Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P07942: Variant p.Gln1022Arg

Laminin subunit beta-1
Gene: LAMB1
Feedback?
Variant information Variant position: help 1022 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamine (Q) to Arginine (R) at position 1022 (Q1022R, p.Gln1022Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (Q) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1022 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1786 The length of the canonical sequence.
Location on the sequence: help YHTEGEHCQFCRFGYYGDAL Q QDCRKCVCNYLGTVQEHCNG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         YHTEGEHCQFCRFGYYGDALQQDCRKCVCNYLGTVQEHCNG

Mouse                         YHTEGDHCQLCQYGYYGDALRQDCRKCVCNYLGTVKEHCNG

Drosophila                    YQTTGDHCELCKDGFFGDALQQNCQQCECDFLGT-----NN

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 22 – 1786 Laminin subunit beta-1
Domain 976 – 1027 Laminin EGF-like 10
Glycosylation 1041 – 1041 N-linked (GlcNAc...) asparagine
Disulfide bond 1012 – 1025



Literature citations
Structure of the human laminin B1 chain gene.
Vuolteenaho R.; Chow L.T.; Tryggvason K.;
J. Biol. Chem. 265:15611-15616(1990)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT ARG-1022; Human laminin B1 chain. A multidomain protein with gene (LAMB1) locus in the q22 region of chromosome 7.
Pikkarainen T.; Eddy R.; Fukushima Y.; Byers M.; Shows T.; Pihlajaniemi T.; Saraste M.; Tryggvason K.;
J. Biol. Chem. 262:10454-10462(1987)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT ARG-1022; Initial characterization of the human central proteome.
Burkard T.R.; Planyavsky M.; Kaupe I.; Breitwieser F.P.; Buerckstuemmer T.; Bennett K.L.; Superti-Furga G.; Colinge J.;
BMC Syst. Biol. 5:17-17(2011)
Cited for: VARIANT [LARGE SCALE ANALYSIS] ARG-1022; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS];
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.